| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
N Engl J Med
|
2011
|
45.46
|
|
3
|
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
|
N Engl J Med
|
2015
|
8.64
|
|
4
|
Improved overall survival in melanoma with combined dabrafenib and trametinib.
|
N Engl J Med
|
2014
|
5.65
|
|
5
|
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
|
J Clin Oncol
|
2013
|
5.36
|
|
6
|
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
|
Cancer Discov
|
2012
|
2.56
|
|
7
|
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.
|
J Clin Oncol
|
2013
|
2.22
|
|
8
|
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
|
Clin Cancer Res
|
2010
|
2.20
|
|
9
|
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
|
Lancet Oncol
|
2013
|
2.13
|
|
10
|
Identifying melanomas in primary care: can we do better?
|
BMJ
|
2012
|
2.01
|
|
11
|
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
|
Am J Pathol
|
2009
|
1.95
|
|
12
|
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
|
J Invest Dermatol
|
2012
|
1.91
|
|
13
|
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
|
J Clin Oncol
|
2007
|
1.79
|
|
14
|
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.
|
Sci Signal
|
2014
|
1.44
|
|
15
|
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
|
Cancer Immunol Immunother
|
2014
|
1.42
|
|
16
|
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.30
|
|
17
|
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
|
Cancer Chemother Pharmacol
|
2013
|
1.28
|
|
18
|
Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers.
|
J Pain Symptom Manage
|
2012
|
1.20
|
|
19
|
Management of small cell lung cancer: recent developments for optimal care.
|
Drugs
|
2012
|
1.13
|
|
20
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
J Clin Oncol
|
2010
|
1.12
|
|
21
|
Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis.
|
J Thorac Oncol
|
2011
|
1.12
|
|
22
|
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
|
Lung Cancer
|
2010
|
1.03
|
|
23
|
Improving outcomes in advanced malignant melanoma: update on systemic therapy.
|
Drugs
|
2005
|
1.01
|
|
24
|
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
|
Cancer Immunol Immunother
|
2009
|
0.99
|
|
25
|
Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.
|
Melanoma Res
|
2014
|
0.96
|
|
26
|
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
|
Health Qual Life Outcomes
|
2012
|
0.92
|
|
27
|
Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone.
|
J Invest Dermatol
|
2002
|
0.91
|
|
28
|
Modern management of small-cell lung cancer.
|
Drugs
|
2007
|
0.88
|
|
29
|
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
|
Lung Cancer
|
2011
|
0.88
|
|
30
|
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
|
Lung Cancer
|
2008
|
0.87
|
|
31
|
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
|
Eur J Cancer
|
2011
|
0.85
|
|
32
|
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
|
Lung Cancer
|
2011
|
0.85
|
|
33
|
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions.
|
Clin Lung Cancer
|
2005
|
0.84
|
|
34
|
Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
|
Expert Rev Anticancer Ther
|
2012
|
0.84
|
|
35
|
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
|
Oncologist
|
2012
|
0.83
|
|
36
|
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
|
Melanoma Res
|
2009
|
0.83
|
|
37
|
Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer.
|
Lung Cancer
|
2012
|
0.82
|
|
38
|
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
|
Melanoma Res
|
2015
|
0.81
|
|
39
|
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
|
Lung Cancer
|
2012
|
0.80
|
|
40
|
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
|
Mol Cancer Ther
|
2004
|
0.80
|
|
41
|
Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals.
|
Support Care Cancer
|
2012
|
0.80
|
|
42
|
Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer.
|
Clin Oncol (R Coll Radiol)
|
2002
|
0.79
|
|
43
|
Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?
|
Drugs
|
2006
|
0.79
|
|
44
|
A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST).
|
Sarcoma
|
2002
|
0.77
|
|
45
|
Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.
|
Clin Cancer Res
|
2005
|
0.76
|
|
46
|
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
|
Pigment Cell Melanoma Res
|
2009
|
0.76
|
|
47
|
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
|
Melanoma Res
|
2011
|
0.76
|
|
48
|
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
|
Cancer
|
2014
|
0.75
|
|
49
|
Efficacy of positron emission tomography staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting.
|
J Thorac Oncol
|
2012
|
0.75
|
|
50
|
Does adjuvant vaccine therapy really have activity in malignant melanoma?
|
J Clin Oncol
|
2007
|
0.75
|
|
51
|
Palliative treatment.
|
Hematol Oncol Clin North Am
|
2004
|
0.75
|
|
52
|
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.
|
Cancer Cell
|
2017
|
0.75
|
|
53
|
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
|
Lung Cancer
|
2011
|
0.75
|
|
54
|
Vemurafenib-induced nonautoimmune haemolytic anaemia.
|
Melanoma Res
|
2014
|
0.75
|
|
55
|
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
|
Expert Rev Anticancer Ther
|
2007
|
0.75
|